Načítá se...
Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
BACKGROUND: Therapeutic drug monitoring of adalimumab (ADM) has been introduced recently. When no detectable ADM serum concentrations can be found, the formation of antidrug antibodies (ADA) should be investigated. A variety of assays to measure the occurrence of ADA have been developed. Results are...
Uloženo v:
| Vydáno v: | Ther Drug Monit |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Therapeutic Drug Monitoring
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218762/ https://ncbi.nlm.nih.gov/pubmed/24906181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FTD.0000000000000074 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|